<DOC>
	<DOCNO>NCT00880568</DOCNO>
	<brief_summary>This study determine recommend clinical dose , evaluate safety , tolerability pharmacokinetics MK-1496 patient locally advance and/or metastatic solid tumor fail standard therapy standard therapy exist , two dose schedule Japan .</brief_summary>
	<brief_title>Phase I Study MK-1496 Patients With Advanced Solid Tumor ( MK-1496-002 AM 4 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Participant must histologicallyconfirmed metastatic locally advanced solid tumor fail respond standard therapy , progress despite standard therapy , standard therapy exist . Participant must Performance Status 0 1 . Participant must adequate organ function . Exclusion Criteria Participant chemotherapy , radiotherapy , biological therapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior registration . Participant receive 4 great regimen chemotherapy ( adjuvant therapy incomplete 1 cycle treatment consider 1 regimen ) . Participant known hypersensitivity component study drug analog . Participant prescription nonprescription drug product know moderate potent inhibitors/inducers cytochrome P ( CYP ) 3A4 , substrates CYP3A4 narrow therapeutic window .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>